# Sidney Kimmel Cancer Center
**Type:** Institutions
**Canonical URL:** https://scholariq.org/institutions/sidney-kimmel-cancer-center/
## Facts
| Field | Value |
| --- | --- |
| Avg h-index | 68.3 |
| Citations | 3,208,026 |
| City | Philadelphia |
| Country | US |
| Description | Sidney Kimmel Cancer Center is a research organisation in Philadelphia, US. OpenAlex records 10,943 works and 3,208,026 citations for it. 1,980 researchers list it as their most recent affiliation. |
| Homepage | https://www.jeffersonhealth.org/clinical-specialties/cancer |
| OpenAlex ID | https://openalex.org/I4210106595 |
| Researchers | 1,980 |
| ROR ID | https://ror.org/010h6g454 |
| Type | healthcare |
| Works | 10,943 |
## University papers
- [Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer](https://scholariq.org/papers/concurrent-chemotherapy-and-radiotherapy-for-organ-preservation-in-advanced/)
- [Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children](https://scholariq.org/papers/efficacy-of-larotrectinib-in-i-trk-i-fusion-positive-cancers-in-adults-and/)
- [Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer](https://scholariq.org/papers/lenvatinib-versus-placebo-in-radioiodine-refractory-thyroid-cancer/)
- [Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer](https://scholariq.org/papers/long-term-results-of-rtog-91-11-a-comparison-of-three-nonsurgical-treatment/)
- [SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas](https://scholariq.org/papers/sox2-is-an-amplified-lineage-survival-oncogene-in-lung-and-esophageal-squamous/)
- [Efficacy of Selpercatinib in RET -Altered Thyroid Cancers](https://scholariq.org/papers/efficacy-of-selpercatinib-in-i-ret-i-altered-thyroid-cancers/)
- [Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer](https://scholariq.org/papers/lenvatinib-plus-pembrolizumab-in-patients-with-advanced-endometrial-cancer/)
- [Outcome of Salvage Total Laryngectomy Following Organ Preservation Therapy](https://scholariq.org/papers/outcome-of-salvage-total-laryngectomy-following-organ-preservation-therapy/)
## University top topics
Showing 8 of 25.
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Prostate Cancer Diagnosis and Treatment](https://scholariq.org/topics/prostate-cancer-diagnosis-and-treatment/)
- [Cancer-related Molecular Pathways](https://scholariq.org/topics/cancer-related-molecular-pathways/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.